A Full Service Intellectual Property Firm

Safeguarding innovation demands proactive IP counsel known for thought leadership and creative legal strategies. Safeguarding innovation demands Oblon.

Firm News

Oblon Professionals Partnered with AIPPI・JAPAN

On September 14, 2018 eight Oblon professionals partnered with AIPPI - JAPAN (The international Association for the Protection of Intellectual Property of Japan) to present an AIPPI ITC Seminar. The seminar was held at the Kanazawa Institute of Technology Tokyo Toranomon Campus.

More
Firm News

Oblon Featured in Alexandria News as the Firm Celebrates It’s 50 Years

Oblon was featured in the Alexandria Newsas the Firm celebrates it's 50 years!

More
Firm News

Oblon’s International Guest Program Welcomes Back Professor Elizabeth Winston

Oblon is honored to welcome back Professor Elizabeth Winston from the Columbus School of Law at The Catholic University of America. Professor Winston is a frequent speaker on a variety of intellectual property topics at conferences around the country.

More

WHAT DOES AND/OR MEAN? IT DEPENDS

In an interesting, but non-precedential, decision from the Court of Appeals for the Federal Circuit (Supernus Pharmaceuticals, Inc. v TWI Pharmaceuticals, Inc  et al(Fed. Cir., September 6, 2018-http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-2513.Opinion.9-6-2018.pdf), the Court affirmed a decision from the U.S. District Court of New Jersey.

More

JTEKT v. GKN: Federal Circuit Finds Competitor Lacks Standing to Appeal PTAB’s Final Written Decision

After determining that its competitor GKN’s patent raised a potential risk of infringement for a product under development, JTEKT[1] challenged the patentability of claims 1–7 of U.S. Patent No. 8,215,440 via inter partes review (IPR2016-00046).  

More

Recent Pharmaceutical House and Senate Bills

Over the summer, representatives introduced bills and amendments of interest to the pharmaceutical industry.  First, Senator Orrin Hatch, co-author of the Hatch-Waxman Act, filed an amendment in the Senate Judiciary Committee that would require a generic manufacturer wishing to challenge a brand-name drug patent to choose between Hatch-Waxman litigation and IPR, removing the option to use both.  

More

Oblon at the NOVA Veteran & Military Family Hiring Expo

Oblon will be participating at the NOVA Veteran & Military Family Hiring Expo on Tuesday, August 28th, 2018, from 11:00am - 2:00pm. 

More

AIPPI ITC Seminar – Japan

You are invited to the AIPPI Japan ITC Seminar to be held on Friday, September 14, 2018 at 13:30-17:00

More

French Association of IP Specialists (ASPI) – France 2018

Philippe Signore has been invited to present by the French Association of IP Specialists (ASPI) and by Groupe Rhone-Alpes pour la Protection de la Propriete Industrielle (GRAPI) as part of their 2018 lecture series in France.

More

Chambers & Partners USA: America’s Leading Lawyers for Business

Oblon is honored to receive a prestigious Band 1 ranking from Chambers & Partners USA. The publication identified the firm as one of Northern Virginia’s leading firms in the area of intellectual property law.

More

Oblon Named a "Best Law Firm" by U.S. News and World Report

Oblon was named one of the “Best Law Firms” in the United States in 2018 by U.S. News and World Report and Best Lawyers.

More

Oblon Honored in The Legal 500 United States 2018

Oblon has been honored by The Legal 500 as one of America's leading firms in the area of patent: Prosecution (including reexamination and Post-Grant Proceedings).

More
Select an Attorney Select a Service Contact Us